Table 4.

One-way sensitivity analyses on the incremental cost-effectiveness ratio of GR risedronate compared to generic risedronate, alendronate, and no treatment in women aged 70 years with BMD T-score ≤ − 2.5 and prevalent vertebral fractures

	GR risedronate
	Vs generic risedronate	Vs alendronate	Vs no treatment
Base-case	2341	2037	Cost-saving
Fracture costs 25% lower	5564	8038	4484
Fracture costs 25% higher	Dominant	Dominant	Cost-saving
Fracture disutilities 25% higher	391	3624	Cost-saving
Fracture disutilities 25% lower	2481	8860	912
Discount rates 5%	7453	7921	937
Excess mortality (50%)	2953	1279	446
GR risedronate cost + 10%	6164	17,978	425
GR risedronate cost − 10%	Dominant	Dominant	Cost-saving
Treatment-specific efficacy data	5141	Dominated	2071
Incremental persistence + 50%	481	1272	–
Incremental persistence + 25%	738	1398	–
Incremental persistence − 25%	6270	4349	–
Incremental persistence − 50%	13,802	9494	–